You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖諾醫藥-B(02257.HK):將在2022年Pre-ASCO中國峯會介紹其RNAi療法於腫瘤學領域臨牀研究結果與發展戰略
格隆匯 05-20 06:10

格隆匯5月20日丨聖諾醫藥-B(02257.HK)發佈公吿,2022年5月20日,公司執行董事兼首席醫務官Michael Molyneaux博士將於2022年Pre-ASCO(美國臨牀腫瘤學會)中國峯會的“中美創新藥的研發進展及監管策略”介紹公司核心產品STP705用以治療非黑色素瘤皮膚癌的臨牀研究結果及公司佈局中美兩國的臨牀發展戰略。2022年Pre-ASCO中國峯會將於2022年5月21日以線上直播形式舉行。

Sirnaomics基於其雙靶向siRNA療法和多肽納米顆粒遞送技術建立了豐富的RNAi療法產品管線,用於治療各種類型的癌症適應症。其中包括首個在臨牀IIa試驗中證實可治療原位鱗狀細胞皮膚癌的STP705,處於治療多種實體瘤(如肝癌)臨牀I期試驗的STP707。除此之外的臨牀前項目,如適用於治療結直腸癌及黑色素瘤的STP355、治療頭頸癌與膀胱癌的STP369及治療膽管癌的STP779已經進入臨牀前後期的IND申請階段,該產品管線的階段性目標為在2023年申請啟動臨牀研究。這些新型RNAi療法項目的發展均依託於公司在中國和美國均擁有重要市場地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account